Acelyrin price target raised to $15 from $13 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on Acelyrin to $15 from $13 and keeps an Overweight rating on the shares. The firm thinks the odds are high that izokibep’s Phase 2/3 trial in uveitis will be positive in Q4. Given where shares are trading, this offers an attractive risk/reward skew of +75%/-10% in Wells’ bull/bear case scenarios, the firm adds.